See more : Arisawa Mfg. Co., Ltd. (5208.T) Income Statement Analysis – Financial Results
Complete financial analysis of ORIC Pharmaceuticals, Inc. (ORIC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ORIC Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- MIND Technology, Inc. (MIND) Income Statement Analysis – Financial Results
- Baylin Technologies Inc. (BYLTF) Income Statement Analysis – Financial Results
- Quadrant Televentures Limited (QUADRANT.BO) Income Statement Analysis – Financial Results
- Franklin BSP Realty Trust, Inc. (FBRT) Income Statement Analysis – Financial Results
- Quest Oil Corporation (QOIL) Income Statement Analysis – Financial Results
ORIC Pharmaceuticals, Inc. (ORIC)
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.03M | 966.00K | 897.00K | 970.00K | 1.00M | 900.00K | 900.00K |
| Gross Profit | -1.03M | -966.00K | -897.00K | -970.00K | -1.00M | -900.00K | -900.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 85.17M | 61.68M | 56.86M | 35.92M | 22.84M | 19.03M | 19.13M |
| General & Administrative | 25.61M | 25.09M | 22.01M | 13.42M | 5.73M | 3.35M | 3.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -900.00K |
| SG&A | 25.61M | 25.09M | 22.01M | 13.42M | 5.73M | 3.35M | 2.52M |
| Other Expenses | 0.00 | 5.00M | 15.00K | 177.00K | 289.00K | 233.00K | 0.00 |
| Operating Expenses | 110.78M | 86.77M | 78.87M | 49.34M | 28.57M | 22.37M | 21.64M |
| Cost & Expenses | 110.78M | 86.77M | 78.87M | 49.34M | 28.57M | 22.37M | 22.54M |
| Interest Income | 10.08M | 2.65M | 141.00K | 306.00K | 1.40M | 775.00K | 251.00K |
| Interest Expense | 0.00 | 2.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.03M | 966.00K | 897.00K | 970.00K | 1.00M | 900.00K | 900.00K |
| EBITDA | -109.75M | -91.77M | -77.97M | -74.19M | -27.54M | -20.46M | -21.13M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -110.78M | -91.77M | -78.87M | -74.19M | -28.57M | -22.37M | -22.54M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.08M | 2.65M | 156.00K | 483.00K | 1.69M | 1.01M | 512.00K |
| Income Before Tax | -100.70M | -89.12M | -78.72M | -73.70M | -26.88M | -21.36M | -22.03M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.36M | -1.04M | 23.57M | -1.40M | -1.01M | 0.00 |
| Net Income | -100.70M | -91.48M | -77.68M | -97.27M | -25.49M | -21.36M | -22.03M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.96 | -2.31 | -2.05 | -4.43 | -0.85 | -1.12 | -0.74 |
| EPS Diluted | -1.96 | -2.31 | -2.05 | -4.43 | -0.85 | -1.12 | -0.74 |
| Weighted Avg Shares Out | 51.45M | 39.66M | 37.95M | 21.94M | 29.90M | 19.14M | 29.90M |
| Weighted Avg Shares Out (Dil) | 51.45M | 39.66M | 37.95M | 21.94M | 29.90M | 19.14M | 29.90M |
ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel
ORIC Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
ORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update
ORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones
ORIC Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports